
    
      This study will assess the safety, tolerability, pharmacokinetics, and efficacy of delamanid
      plus an optimized background regimen in pediatric participants with MDR-TB over a 6-month
      treatment period. This long-term study, an extension of Study 242-12-232, will be conducted
      in participants who have completed Study 242-12-232.
    
  